# A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

> **NCT07082452** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 262 (estimated)

## Conditions studied

- Leukemia, B-Cell, Chronic
- Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT07082452
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2030-09
- **Final completion:** 2031-03
- **Target enrollment:** 262 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082452, "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07082452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*